UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

August 30, 2024

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

August 29, 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

August 29, 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

August 28, 2024

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

August 26, 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

August 22, 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

August 22, 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

August 15, 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

August 15, 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

August 01, 2024

Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.

July 31, 2024

Deborah J. Wong, MD, PhD, discusses challenges incorporating checkpoint inhibitors into curative-intent approaches for patients with head and neck squamous cell carcinoma.

July 29, 2024

The panel looks to the future landscape for HER2+ breast cancer, highlighting emerging treatment practices and currently unmet needs.

July 29, 2024

Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.

July 22, 2024

Breast cancer specialists discuss adverse events associated with T-DXd, focusing on monitoring for interstitial lung disease (ILD) and the role of re-challenging patients with T-DXd after resolution of grade 1 ILD.

July 22, 2024

Aditya Bardia, MD, MPH, shares comprehensive insights on the DESTINY-Breast06 study evaluating T-DXd in HER2-low and HER2 ultra-low metastatic breast cancer, and the panel offers its initial impressions.

July 15, 2024

Ian Krop, MD, PhD, provides an overview of HER2-low and HER2 ultra-low breast cancer and discusses challenges encountered during diagnosis.

July 15, 2024

Experts on breast cancer discuss the potential impact of ongoing research in HER2+ breast cancer, highlighting how results from the DESTINY-Breast07 study may translate to DESTINY-Breast09.

July 08, 2024

Melinda Telli, MD, provides an overview of ongoing research in HER2+ metastatic breast cancer, highlighting the DESTINY-Breast09, PATINA, INAVO122, and HER2CLIMB-05 studies.

July 08, 2024

The panel provides comprehensive insights on approaching first-line treatment of patients with HER2+ metastatic breast cancer and the role of neratinib.